These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11189688)

  • 1. Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years.
    Simpson NK; Johnson CC; Ogden SL; Gamito E; Trocky N; McGuire C; Martin J; Barrow S; Lamerato L; Flickinger LM; Broski KG; Engelhard D; Hilke C; Bonk J; Gahagan B; Gren LH; Childs J; Lappe K; Fouad M; Thompson J; Sullivan D;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):356S-378S. PubMed ID: 11189688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing Multi-Center Recruitment in the PLCO Cancer Screening Trial.
    Gohagan JK; Broski K; Gren LH; Fouad MN; Higgins D; Lappe K; Ogden S; Shambaugh V; Pinsky PF; O'Brien B; Yurgalevich S; Riley T; Wright P; Prorok PC
    Rev Recent Clin Trials; 2015; 10(3):187-93. PubMed ID: 26435288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
    Gohagan JK; Prorok PC; Hayes RB; Kramer BS;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Stallings FL; Ford ME; Simpson NK; Fouad M; Jernigan JC; Trauth JM; Miller DS;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):379S-389S. PubMed ID: 11189689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recruitment in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: the first phase of recruitment at Henry Ford Health System.
    Lamerato LE; Marcus PM; Jacobsen G; Johnson CC
    Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):827-33. PubMed ID: 18398023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Pinsky PF; Ford M; Gamito E; Higgins D; Jenkins V; Lamerato L; Tenorio S; Marcus PM; Gohagan JK
    J Natl Med Assoc; 2008 Mar; 100(3):291-8. PubMed ID: 18390022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Miller AB; Yurgalevitch S; Weissfeld JL;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):400S-406S. PubMed ID: 11189691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Weissfeld JL; Fagerstrom RM; O'Brien B;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):390S-399S. PubMed ID: 11189690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Andriole GL
    Recent Results Cancer Res; 2014; 202():53-7. PubMed ID: 24531777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coordination and management of a large multicenter screening trial: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    O'Brien B; Nichaman L; Browne JE; Levin DL; Prorok PC; Gohagan JK;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):310S-328S. PubMed ID: 11189685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recruitment methods employed in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Gren L; Broski K; Childs J; Cordes J; Engelhard D; Gahagan B; Gamito E; Gardner V; Geisser M; Higgins D; Jenkins V; Lamerato L; Lappe K; Lowery H; McGuire C; Miedzinski M; Ogden S; Tenorio S; Watt G; Wohlers B; Marcus P
    Clin Trials; 2009 Feb; 6(1):52-9. PubMed ID: 19254935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Prorok PC; Andriole GL; Bresalier RS; Buys SS; Chia D; Crawford ED; Fogel R; Gelmann EP; Gilbert F; Hasson MA; Hayes RB; Johnson CC; Mandel JS; Oberman A; O'Brien B; Oken MM; Rafla S; Reding D; Rutt W; Weissfeld JL; Yokochi L; Gohagan JK;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):273S-309S. PubMed ID: 11189684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and evolution of the data management systems in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Hasson MA; Fagerstrom RM; Kahane DC; Walsh JH; Myers MH; Caughman C; Wenzel B; Haralson JC; Flickinger LM; Turner LM;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):329S-348S. PubMed ID: 11189686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Quality Management (CQM) in the PLCO Trial.
    Gohagan JK; O'Brien B; Hasson MA; Umbel KD; Bridgeman B; Kramer BS; Reding D; Gren L; Wright P; Riley T; Prorok PC
    Rev Recent Clin Trials; 2015; 10(3):223-32. PubMed ID: 26238118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results.
    Gohagan JK; Prorok PC; Greenwald P; Kramer BS
    Rev Recent Clin Trials; 2015; 10(3):173-80. PubMed ID: 26238115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting older african american women's decisions to join the PLCO Cancer Screening Trial.
    Trauth JM; Jernigan JC; Siminoff LA; Musa D; Neal-Ferguson D; Weissfeld J
    J Clin Oncol; 2005 Dec; 23(34):8730-8. PubMed ID: 16314633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial.
    Hayes RB; Reding D; Kopp W; Subar AF; Bhat N; Rothman N; Caporaso N; Ziegler RG; Johnson CC; Weissfeld JL; Hoover RN; Hartge P; Palace C; Gohagan JK;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):349S-355S. PubMed ID: 11189687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A different interpretation of the efficacy of lung cancer screening in the PLCO trial.
    Sagawa M; Nakayama T; Sobue T;
    Eur J Epidemiol; 2016 Feb; 31(2):211-2. PubMed ID: 26197850
    [No Abstract]   [Full Text] [Related]  

  • 19. ERSPC, PLCO studies and critique of cochrane review 2013.
    Schröder FH
    Recent Results Cancer Res; 2014; 202():59-63. PubMed ID: 24531778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies.
    Ilic D
    Recent Results Cancer Res; 2014; 202():65-71. PubMed ID: 24531779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.